Saved source record
Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK.
This is a source-metadata record last found in a complete check on Sep 28, 2026. It is not a Pependium assessment of safety or effectiveness. Check the original sources for current details, corrections and full methods.
Source status: This saved record has not yet had a scheduled exact-ID status check. Check its original source links.
Study metadata
- Study type
- Original analysis
- Study category (metadata hint)
- Economic model
- Source date
- Published: 2026-03-02
- Authors
- Kanumilli N, Osumili B, Evans J, Webb J, Buckingham M, Debackere N, Nowakowski P, Cattin J
- Journal or registry
- Not reported
- Registry study design
- Not reported
- Registry enrollment
- Not reported
- Funding agencies
- Not reported in source metadata
- Identifiers
- DOI: 10.1080/13696998.2026.2631920 · PMID: 41771166
- First found
- Sep 28, 2026
- Last found
- Sep 28, 2026
Original sources
Browse saved studies · Search live sources